Molecular biology of squamous cell carcinoma of the head and neck: Relevance and therapeutic implications

Expert Review of Anticancer Therapy

Volumn 10, Issue 9, 2010, Pages 1471-1484

  Schmitz, Sandra ^a,b   MacHiels, Jean Pascal ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

angiogenesis; clinical implications; epidermal growth factor; hepatocyte growth factor; insulin like growth factor; molecular pathways; risk factors; squamous cell carcinoma of the head and neck; targeted therapy

Indexed keywords

ADVEXIN; ALCOHOL; BETEL EXTRACT; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC A12; NGN 201; PANITUMUMAB; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TOBACCO SMOKE; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ADD ON THERAPY; ANGIOGENESIS; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; DENTURE; DYSPHAGIA; FANCONI ANEMIA; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR BIOLOGY; MOUTH HYGIENE; RECOMMENDED DRUG DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; SYPHILIS; WART VIRUS; XERODERMA PIGMENTOSUM;

ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 77956711108     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.115     Document Type: Review

References (123)

1. Wilson DM, Bohr VA. The mechanics of base repair, and its relationship to aging and disease. DNA Repair 6(4), 544-559 (2007).
2. Li C, Hu Z, Lu J et al. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1 and APE1 and the risk of squamous cell carcinoma in head and neck. Cancer 110(4), 867-875 (2007).
3. Haudra-Luca A, Hernandez J, Mountzios G. Excision repair cross complementation group I immunohistochemical expression predicts objective response and cancer specifc survival in patients treated by cisplatin based induction chemotherapy for locally advanced head and neck squamous cell carcnoma. Clin. Cancer Res. 13(13), 3855-3859 (2007).
4. Ho T, Wei Q, Sturgis EM. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 29, 682-699 (2007).
5. Zafereo ME, Sturgis EM, Liu Z, Wang LE, Wei Q, Li G. Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis 30(6), 997-1002 (2009).
6. Anantharaman D, Chaubel PM, Kannan S, Bhisey RA, Mahimkar MB. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 28, 1455-1462 (2007).
7. Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res. Health 30, 38-41, 44-47 (2007).
8. Rosenquist K, Wennerberg J, Schildt EB et al. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol. 125, 1327-1336 (2005).
9. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas wordwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 14(2), 467-475 (2005).
10. Fakhry C, Gillisson ML. Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol 24(17), 2606-2611 (2006).
11. Gillison ML, D'Souza G, Westra W et al Distinct risk factor profles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 100, 407-420 (2008).
12. Narisawa-Saito M, Kiyono T. Basic mechanisms of high risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 98, 1505-1511 (2007).
13. Slebos RJ, Yi Y, Ely K et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin. Cancer Res. 12(3 Pt 1), 701-709 (2006).
14. Weinberger PM, Yu Z, Kountourakis P et al. Defning molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol. Head Neck Surg. 141(3), 382-389 (2009).
15. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP. Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect. Agent Cancer 5, 4 (2010).
16. Gillison ML, Harris J, Westra W et al.; Radiation Therapy Oncology Group. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J. Clin. Oncol 27(15 Suppl.) (2009) (Abstract 6003).
17. Maxwell JH, Kumar B, Feng FY et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 16, 1226-1235 (2010).
18. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection review and meta-analysis. Int. J. Cancer 121(8), 1813-1820 (2007).
19. Fakhry C, Westra WH, Li S et al Improved survival in patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst. 100, 261-269 (2008).
20. Budrukkar A, Shahid T, Murthy V Squamous cell carcinoma of base of tongue in a patient with Fanconi's anemia treated with radiation therapy: case report and review of literature. Head Neck DOI: 10.1002/hed.21211 (2009) (Epub ahead of print).
21. Prime SS, Thakker NS, Pring M, Guest PG, Paterson IC. A review of inherited cancer syndroms and their relevance to oral squamous cell carcinoma. Oral Oncol 37(1), 1-16 (2001).
22. Califano J, Van Der Riet P, Westra W Genetic progression model for head and neck cancer: implications for feld cancerization. Cancer Res. 56(11), 2488-2492 (1996).
23. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 5(4), 311-316 (2004).
24. Singh B, Reddy PG, Goberdhan A et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Gene Dev. 16, 984-993 (2002).
25. Klussmann JP, Mooren JJ, Lehnen M et al Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin. Cancer Res. 15(5), 1779-1786 (2009).
26. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006).
27. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24(17), 2666-2672 (2006).
28. Rubin Grandis JR, Melhem MF, Gooding WE et al. Levels of TGFA and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90(11), 824-832 (1998).
29. Psyrri A, Yu Z, Weinberger PM et al Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res. 11, 5856-5862 (2005).
30. Hanada N, Lo HW, Day CP et al. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog. 45, 10-17 (2006).
31. Lo HW, Hsu SC, Ali-Seyed M et al. Nuclear interaction of EGFR and STAT3 in the activation of iNOS/No pathway. Cancer Cell 7(6), 575-589 (2005).
32. Hung Y, Tseng JT, Lee YC et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acid Res. 36, 4337-4351 (2008).
33. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinoma. Neoplasma 52, 338-343 (2005).
34. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176 (2006).
35. Temam S, Kawaguchi H, El-Naggar AK et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome. J. Clin. Oncol. 25, 2164-2170 (2007).
36. Chiang WF, Liu SY, Yen CY et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplifcation with neck lymph node metastasis in areca-associated oral carcinoma. Oral Oncol. 44, 270-276 (2008).
37. Dittmann K, Mayer C, Fehrenbacher B et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 280(35), 31182-31189 (2005).
38. Dittmann K, Mayer C, Ohneseit PA et al. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA repair: a COX-2 independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 70(1), 203-212 (2008).
39. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother. Oncol. 76(2), 157-161 (2005).
40. Walker F, Zhang HH, Burgess AW. Identifcation of a novel EGF-sensitive cell cycle checkpoint. Exp. Cell Res. 313(3), 511-526 (2007).
41. Milas L, Mason K, Hunter N. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin. Cancer Res. 6, 701-708 (2000).
42. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234-3243 (2001).
43. Bonner JA, Harari PM, Giralt J et al Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
44. Bonner JA, Harari PM, Giralt J et al Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial and relation between cetuximab-induced rush and survival. Lancet Oncol. 11(1), 21-28 (2010).
45. Pfster DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot Phase II study for a new combined-modality paradigm. J. Clin. Oncol. 24, 1072-1078 (2006).
46. Vermorken J, Mesia R, Rivera F et al Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
47. Mesía R, Rivera F, Kawecki A et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab frst line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. DOI: 10.1093/annonc/mdq077 (2010) (Epub ahead of print).
48. Herbst RS, Arquette M, Shin DM. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5578-5587 (2005).
49. Baselga J, Trigo JM, Bourhis J et al Phase II multicenter study of the epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of head and neck. J. Clin. Oncol. 23, 5568-5577 (2005).
50. Ahsan A, Hiniker SM, Ramanand SG et al. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 70(7), 2862-2869 (2010).
51. Machiels JP, Subramian S, Ruzsa A et al. An open-label, randomized Phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy. Presented at: 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 4-8 June 2010.
52. Cohen E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24, 2659-2665 (2006).
53. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A Phase III randomized, placebo-controlled trial of docetaxel (D) with or without geftinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol 27(15S) (2009) (Abstract 6011).
54. Stewart JS, Cohen EE, Licitra L et al Phase III study of geftinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27, 1864-1871 (2009).
55. Grégoire V, Raben D. A Phase II randomised, double-blind, placebo-controlled study of geftinib 250 or 500 mg given either continuously or concomitantly with cisplatin/radiotherapy for the treatment of previously untreated, unresected, late stage III/IV non-metastatic head and neck squamous cell carcinoma (Study 1839IL/0706). Presented at: 2nd International Conference on Innovative Approaches in Head & Neck Oncology. Barcelona, Spain, 26-28 February 2009.
56. Thomas F, Rochaix P, Benlyazid A. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 13(23), 7086-7092 (2007).
57. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
58. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
59. Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFR VIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12, 5064-5073 (2006).
60. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 16, 2489-2495 (2010).
61. Cavalot A, Martone R, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of Her-2/neu expression in head and neck carcinomas. Head Neck 29(7), 655-664 (2007).
62. Ekberg T, Nestor M, Engstrom M et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of oral cavity and base of tongue. Int. J. Oncol. 26(5), 1177-1185 (2005).
63. Del Sordo R, Angiero F, Bellezza G et al. A HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological signifcance. J. Oral Pathol. Med. 39, 79-78 (2010).
64. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19, 2013-2023 (2007).
65. Abidoye OO, Cohen EE, Wong SJ et al. A Phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. 24(Suppl. 18) (2006) (Abstract 5568).
66. Torres MA, Raju U, Molkentine D, Riesterer O, Milas L, Ang KK. AC 480, formerly BMS-599626, a pan HER inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. DOI: 10.1007/s10637-010-9389-3 (2010) (Epub ahead of print).
67. Knowles LM, Stabile LP, Egloff AM et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 15(11), 3740-3750 (2009).
68. Birchmeier C, Birchmeier W, Gherardi E, Van De Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 4, 915-925 (2003).
69. Maulik G, Madhiwala P, Brooks S et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J. Cell. Mol. Med. 6(4), 539-553 (2002).
70. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway J. Thorac. Oncol. 1(1), 7-9 (2006).
71. Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol. Cancer 6, 69 (2007).
72. Lee KH, Choi EY, Hyun MS et al. Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur. Surg Res. 39(4), 208-215 (2007).
73. Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 109(5), 687-693 (1999).
74. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab. Invest. 88(4), 342-353 (2008).
75. Akervall J, Guo X, Qian CN et al. Genetic and expression profles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin. Cancer Res. 10(24), 8204-8213 (2004).
76. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplifcation leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
77. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin. Oncol. 35(3), 286-297 (2008).
78. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor geftinib. Cancer Res. 67(19), 9304-9314 (2007).
79. Wheeler DL, Huang S, Kruser TJ et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27(28), 3944-3956 (2008).
80. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfore A. In IGF-I receptor-defcient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21(54), 8240-8250 (2002).
81. Resnicoff M, Abraham D, Yutanawiboonchai W et al. The insulinlike growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55(11), 2463-2469 (1995).
82. Pollak MN, Schernhammer ES, Hankinson SA. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4(7), 505-518 (2004).
83. Jun H, Chang M, Ko Y et al. Clinical signifcance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6036).
84. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin. Cancer Res. 13 (14), 4291-4299 (2007).
85. Schmitz S, Kaminsky MC, Henry S et al. Phase II study of fgitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-2002. Presented at: 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 4-8 June 2010.
86. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28(34), 3009-3021 (2009).
87. Huang F, Greer A, Hurlburt W et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69(1), 161-170 (2009).
88. Morgillo F, Woo JK, Kim ES, Hong WL, Lee HY Heterodimerization of insulin-like growth factor receptor /epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66(20), 10100-10111 (2006).
89. Calvani M, Rapsiarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic induction of an HIF-1a-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107(7), 2705-2712 (2006).
90. Lewis CE, Hughes R. Infammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 9(3), 209 (2007).
91. Jiang Y, Dai A, Li Q, Hu R. Hypoxia induces transforming growth factor b1 gene expression in the pulmonary artery of rats with hypoxia-inductible factor-1a. Acta Biochim. Biophys. Sin. 39(1), 73-80 (2007).
92. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defned by pericyte coverage of the performed endothelial network and is regulated by BDGF-B and VEGF. Development 125(9), 591-1598 (1998).
93. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF-and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004).
94. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefts of targeted both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111(9), 1287-1295 (2003).
95. Neuchrist C, Erovic BM, Handisurya et al. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111, 1834-1841 (2001).
96. Neuchrist C, Erovic BM, Handisurya et al. Vascular endothelial growth factor receptor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25, 464-474 (2003).
97. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic signifcance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin. Cancer Res. 11, 1434-1440 (2005).
98. Williamson SK, Moon J, Huang CH et al. A Phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 6044).
99. Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25, 3766-3773 (2007).
100. Machiels JP, Henry S, Zanetta S et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-2001. J. Clin. Oncol. 28(1), 21-28 (2010).
101. Naumov GN, Nilsson MB, Cascone T et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15, 3484-3494 (2009).
102. Cohen EE, Davis DW, Karrison TG et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a Phase I/II study. Lancet Oncol. 10(3), 247-257 (2009).
103. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 52(21), 5997-6000 (1992).
104. Boyle JO, Hakim J, Koch WM et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53(19), 4477-4480 (1993).
105. Tolcher AW, Hao D, De Bono J et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J. Clin. Oncol. 24, 2052-2058 (2006).
106. Nemunaitis J, Clayman G, Agarwala SS et al. Biomarkers predict p53 gene therapy effcacy in recurrent squamous cell carcinoma of the head and neck. Clin. Cancer Res. 15(24), 7719-7725 (2009).
107. Moro L, Dolce L, Cabodi S et al. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specifc EGF receptor tyrosines. J. Biol. Chem. 277(11), 9405-9414 (2002).
108. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 96(4), 1415-1420 (1999).
109. Zhang Q, Thomas SM, Xi S et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 64(17), 6166-6173 (2004).
110. Wheeler DL, Lida M, Kruser TJ et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol. Ther. 8, 696-703 (2009).
111. Koppikar P, Choi SH, Egloff AM et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin. Cancer Res. 14(13), 4284-4291 (2008).
112. Brooks HD, Glisson B, Lu C et al. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6022).
113. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5), 417-421 (2004).
114. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 29(10), 959-971 (2007).
115. Chen Z, Ricker JL, Malhotra PS et al. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kB and activator protein-1 related mechanisms. Mol. Cancer Ther. 7(7), 1949-1960 (2008).
116. Li C, Zang Y, Sen M et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol. Cancer Ther. 8(8), 2211-2220 (2009).
117. Gilbert J, Lee J, Argiris A et al. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 27(15 Suppl.) (2009) (Abstract 6020).
118. Amornphimoltham P, Patel V, Sodhi A et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 65(21), 9953-9961 (2005).
119. Argiris A, Cohen E, Karrison T et al. A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol. Ther. 5(7), 766-770 (2006).
120. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem. 32, 17-29 (1997).
121. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin. Cancer Res. 11(10), 3889-3896 (2005).
122. Russel JS, Burgan W, Oswald KA, Camphausen K, Toflon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin. Cancer Res. 9(10 Pt 1), 3749-3755 (2003).
123. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int. J. Cancer 126, 1216-1225 (2010).